Moreover, there was an inverse correlation between PTEN and BUB1B expression in GBM patients with low survival (Figure 2D; less than 12 months; n=15, p<0.001, pearson −0.7592) further supporting that targeting BUBR1 (as PARPi does) could be used as rational therapy in PTEN deficient GBM. Here, BUB1B is linked to glioblastoma.